- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Eisai To Present New Data For Gastrointestinal Cancer Research at ASCO GI 2024
The data was collected during the LEAP clinical program, developed in partnership with Merck.
Eisai, a Japanese-based pharmaceutical company, announced that it will be presenting new gastrointestinal cancer research data at the American Society of Clinical Oncology’s (ASCO) 2024 symposium. The annual event is scheduled to occur in San Francisco, California, between January 18-20.
According to a press release from the company, Eisai and Merck previously entered into a partnership to co-develop the cancer drug Lenvima. The drug has been designed to work on its own and also in coordination with Merck’s other drug, Keytruda. Both companies will also work together in the commercialization of the drug.
At the upcoming event, Eisai announced that it will be presenting data from the LEAP clinical program. LEAP (which is short for Lenvatinib and Pembrolizumab) was developed to study the effectiveness of using Keytruda and Lenvima together to treat various types of tumors.
In the same press release, Eisai’s chief scientific officer and senior vice president Dr. Takashi Owa said, “We look forward to convening in San Francisco to share longer-term efficacy and safety results from the Phase 3 LEAP-002 trial with the scientific community at ASCO GI 2024. We are proud of the role that Lenvima monotherapy plays as a first-line treatment for patients with unresectable hepatocellular carcinoma, particularly as the global burden of liver cancer rises. Our data at the symposium illustrate Eisai's commitment to contribute to the understanding of gastrointestinal cancers with the aim of making a difference in the lives of patients and their families."
Lenvima is indicated for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. The drug can also be used in combination with a variety of other treatments for patients suffering from multiple conditions, such as renal cell carcinoma, unrespectable hepatocellular carcinoma, and advanced endometrial carcinoma.
The drug has shown effectiveness at inhibiting kinases that impact pathogenic angiogenesis, tumor growth, and cancer progression.
Eisai is scheduled to present the data on January 19, 2024, at 12:30 pm PST.
SOURCE
(Jan. 16, 2024); Eisai Inc.; Eisai Furthers Oncology Research in Gastrointestinal Cancer Treatment with New Data at ASCO GI 2024; https://www.prnewswire.com/news-releases/eisai-furthers-oncology-research-in-gastrointestinal-cancer-treatment-with-new-data-at-asco-gi-2024-302033775.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
